AEGiS-FDA: FDA Approval of New, 10 Minute Rapid HIV Test

Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.

FDA Approval of New, 10 Minute Rapid HIV Test

Food and Drug Administration - January 2, 2004
Richard Klein, Office of Special Health Issues

FDA approved, on December 23, 2003, the Uni-Gold Recombigen(TM) HIV rapid HIV test, a single use rapid test for the detection of antibodies to HIV-1 in plasma, serum and whole blood (venipuncture). It is the first device to be FDA approved for use with all three sample types. Uni-Gold Recombigen HIV is intended for use in point of care settings as an aid in diagnosis of infection with HIV-1.

Use of Uni-Gold Recombigen HIV is restricted to clinical laboratory professionals in facilities having an adequate quality assurance program. The test is not approved to screen donors of blood, plasma, cells or tissues, or for home use.

Uni-Gold Recombigen HIV provides results in 10 minutes. It was approved by the FDA on the basis of clinical trial results demonstrating test sensitivity of 100% and specificity of over 99.7%.

Test subjects must receive the "Subject Information Leaflet" prior to specimen collection, and appropriate counseling when test results are provided.

Positive test results require confirmation. The test is suitable for use in appropriate multi-test algorithms designed for the statistical validation of rapid HIV test results.

Product labeling will be available in the coming weeks at http://www.fda.gov/cber/products/testkits.htm

The Uni-Gold Recombigen HIV test is made by Trinity Biotech plc of Bray, Ireland, and distributed in the U.S. by Trinity Biotech USA, Jamestown, NY.
040102
FD040101

SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .